The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2023 | Management of anemia in LR-MDS & overcoming treatment failure in HR-MDS
In this discussion, Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, and Valeria Santini, MD, University of Florence, Florence, Italy, share their highlights from the 2023 MDS meeting, commenting on current and emerging treatment strategies for patients with lower-risk myelodysplastic syndromes (LR-MDS) with anemia, and debating how to improve clinical outcomes for patients with higher-risk disease. This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
